Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases TranscriptSeeking Alpha • 11/05/25
NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs AdvisorGlobeNewsWire • 09/23/25
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025The Motley Fool • 09/03/25
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the ClinicBusiness Wire • 08/11/25
Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve StrategyBusiness Wire • 08/04/25
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of ImmunologistsBusiness Wire • 05/06/25
Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 04/01/25
Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease PatientsBenzinga • 03/27/25
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical HighlightsBusiness Wire • 03/27/25
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host DiseaseBusiness Wire • 03/27/25
Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain StockZacks Investment Research • 02/10/25
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative ColitisBusiness Wire • 02/06/25
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical UpdatesBusiness Wire • 11/13/24
Equillium Announces Poster Presentation at the Society for Immunotherapy of CancerBusiness Wire • 11/12/24
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 11/06/24